Biocon Biologics has reached a settlement and licence agreement with Janssen Biotech, Janssen Sciences Ireland and Johnson & Johnson (collectively called Janssen) for the commercialisation of Bmab ...
Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. This is an ...
Analysis of KRAS/NRAS, PI3CA, and BRAF mutations in the phase II KSCC0901 study of cetuximab plus S-1 as third-line treatment for metastatic colorectal cancer in Japanese patients. This is an ASCO ...
Under the terms of the settlement agreement, the biosimilar company has resolved patent disputes with Janssen to secure market entry dates in Europe, particularly the United Kingdom (UK), Canada, and ...
Biocon Biologics, a subsidiary of Biocon Ltd, has signed a settlement and license agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson, collectively known as Janssen.
Biocon Biologics has signed a settlement and license agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) that clears the way to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results